Access the full text.
Sign up today, get DeepDyve free for 14 days.
V. Joukov, K. Pajusola, A. Kaipainen, D. Chilov, I. Lahtinen, E. Kukk, O. Saksela, N. Kalkkinen, K. Alitalo (1996)
A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases.The EMBO Journal, 15
O. Frazier, R. March, K. Horvath (1999)
Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease.The New England journal of medicine, 341 14
D. Esakof, M. Maysky, Douglas Losordo, P. Vale, K. Lathi, J. Pastore, J. Symes, J. Isner (1999)
Intraoperative multiplane transesophageal echocardiography for guiding direct myocardial gene transfer of vascular endothelial growth factor in patients with refractory angina pectoris.Human gene therapy, 10 14
Douglas Losordo, P. Vale, R. Hendel, C. Milliken, F. Fortuin, Nancie Cummings, R. Schatz, T. Asahara, J. Isner, R. Kuntz (2002)
Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial IschemiaCirculation: Journal of the American Heart Association, 105
F. Celletti, J. Waugh, P. Amabile, A. Brendolan, P. Hilfiker, M. Dake (2001)
Vascular endothelial growth factor enhances atherosclerotic plaque progressionNature Medicine, 7
K. Moulton, E. Heller, M. Konerding, E. Flynn, W. Palinski, J. Folkman (1999)
Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.Circulation, 99 13
G. Stone, P. Teirstein, R. Rubenstein, Dwayne Schmidt, P. Whitlow, E. Kosinski, G. Mishkel, J. Power (2002)
A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions.Journal of the American College of Cardiology, 39 10
Hendel Hendel, Vale Vale, Losordo Losordo (2000)
The effects of VEGF‐2 gene transfer on rest and stress myocardial perfusion: results of serial SPECT imagingCirculation, 102
M. Jeltsch, A. Kaipainen, V. Joukov, Xiaojuan Meng, M. Lakso, H. Rauvala, M. Swartz, D. Fukumura, R. Jain, K. Alitalo (1997)
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.Science, 276 5317
Aaberge Aaberge, Nordstrand Nordstrand, Dragsund Dragsund (2000)
Transmyocardial revascularization with CO 2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian randomized trialJ Am Coll Cardiol, 35
B. Witzenbichler, T. Asahara, T. Murohara, Marcy Silver, I. Spyridopoulos, M. Magner, Nicole Principe, M. Kearney, Jing-Shan Hu, J. Isner (1998)
Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia.The American journal of pathology, 153 2
J. Symes, Douglas Losordo, P. Vale, K. Lathi, D. Esakof, M. Mayskiy, J. Isner (1999)
Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.The Annals of thoracic surgery, 68 3
K. Allen, R. Dowling, T. Fudge, Phillip Schoettle, Selinger Sl, D. Gangahar, W. Angell, M. Petracek, C. Shaar, W. OʼNEILL (1999)
Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina.The New England journal of medicine, 341 14
L. Aaberge, K. Nordstrand, M. Dragsund, K. Saatvedt, K. Endresen, S. Golf, O. Geiran, M. Abdelnoor, K. Forfang (2016)
Transmyocardial Revascularization Transmyocardial Revascularization With CO 2 Laser in Patients With Refractory Angina Pectoris Clinical Results from The Norwegian Randomized Trial
Background: The short‐term clinical impact of intramyocardial gene transfer (GT) of the angiogenic protein vascular endothelial growth factor‐2 (VEGF‐2) has been previously reported to significantly reduce Canadian Cardiovascular Society (CCS) angina class and to prolong exercise treadmill test (ETT) time. We describe the safety and long‐term events (>1 year) in consecutive, nonrandomized, patients who received intramyocardial VEGF‐2. Methods: Thirty patients with intractable CCS class III or IV angina and no options for revascularization underwent direct intramyocardial GT of VEGF‐2 naked DNA via limited thoracotomy at total doses of 0.2, 0.8, or 2.0 mg. Patients were followed for clinical events after 1 year by hospital records, follow‐up visits or telephone contact. Due to one perioperative death, 29 patients were followed. Results: At a mean follow‐up of 751 ± 102.5 days (range 459–959) there were four deaths (13.8%), five myocardial infarctions (MIs) (17.2%), and seven revascularization procedures (24.1%). There were 15 hospitalizations in 12 patients. At the end of the follow‐up period no patient (0%) had CCS class IV angina, 3 patients (11.5%) had class III angina, and 23 (88.5%) had class I to II angina. There were two new diagnoses of cancer. Conclusion: Transthoracic intramyocardial injection of VEGF‐2 is associated with an improvement of symptoms of angina in the majority of patients beyond the first year of treatment. Major clinical events such as death, MI, and repeat revascularization are uncommon during the first year but more frequent after 1 year at a rate consistent with the severity of underlying disease in this population with advanced atherosclerosis. The majority of events were the result of progression of disease in areas of the heart remote from the site of GT. A large randomized trial is planned to determine the efficacy of intramyocardial VEGF‐2 injections in inoperable patients.
Journal of Interventional Cardiology – Wiley
Published: Feb 1, 2005
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.